The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).
 
Zeynep Eroglu
Consulting or Advisory Role - Eisai; Elsevier; Genentech/Roche; OncoSec; Pfizer; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Janice M. Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Bristol-Myers Squibb; celled; Eisai; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); Incyte (Inst); Kinnate Biopharma (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Kari Lynn Kendra
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Isarti Oncology (Inst); Merck (Inst); Novartis (Inst)
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Checkmate Pharmaceuticals (Inst); Idera (Inst); Instil Bio (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Regeneron
 
April K.S. Salama
Consulting or Advisory Role - Iovance Biotherapeutics; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Merck (Inst); Replimune (Inst); Seagen (Inst)
 
Gary C. Doolittle
No Relationships to Disclose
 
Jeffrey A. Sosman
Honoraria - Apexigen; Aveo; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Iovance Biotherapeutics; Jazz Pharmaceuticals
 
Jennifer Brooke Valerin
Speakers' Bureau - AstraZeneca
 
Theresa Michelle Medina
Research Funding - Agenus (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Day One Biopharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); InflaRx (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst)
 
Jose Lutzky
Consulting or Advisory Role - Castle Biosciences; Castle Biosciences; Eisai; Iovance Biotherapeutics; Sapience Therapeutics
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Ultimovacs (Inst); Vyriad (Inst)
 
Stergios J. Moschos
No Relationships to Disclose
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune
 
Joseph Markowitz
Stock and Other Ownership Interests - Aflac; Amdocs; Consolidated Edison; CVS; Intel
Honoraria - Springer
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Jackson Laboratory for Genomic Medicine (Inst); Merck (Inst); Microba (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Naoko Takebe
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Laura W. Knight
No Relationships to Disclose
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)